Aims Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis
(ST) and bleeding, standardized and clinically validated thresholds for accurate risk …

P2Y12 inhibitors are widely used in patients with acute coronary syndromes and in the
secondary prevention of thrombotic events in vascular diseases. Within the past few years …

Optimizing outcomes after percutaneous coronary intervention (PCI) requires balancing
between the risks of thrombotic and bleeding events in individual patients. 1–3 However …

Mechanism-based therapy centred on the molecular understanding of disease-causing
pathways in a given patient is still the exception rather than the rule in medicine, even in …

The existence of poor biological response to clopidogrel has been shown in some patients.
Despite the increasing number of studies, this phenomenon remains difficult to quantify. We …

Platelets are key players in atherothrombosis. Antiplatelet therapy comprising aspirin alone
or with P2Y 12-inhibitors are effective for prevention of atherothrombotic complications …

The crucial role of platelets in primary hemostasis and repair of injured endothelium is well
established, as is their role in atherothrombosis. No other single cell type is responsible for …

Antiplatelet therapy with P2Y12-receptor inhibitors has become the cornerstone of medical
treatment in patients with acute coronary syndrome treated with percutaneous coronary …

Within the past decade, high on-treatment platelet reactivity (HTPR) on clopidogrel and its
clinical implications have been frequently discussed. Although it has been previously …

Antiplatelet therapy with P2Y12 receptor inhibitors has become the cornerstone of medical
treatment in patients with acute coronary syndrome, after percutaneous coronary …